Literature DB >> 28990193

Antimicrobial peptides as a possible interlink between periodontal diseases and its risk factors: A systematic review.

S Li1, G Schmalz1, J Schmidt1, F Krause1, R Haak1, D Ziebolz1.   

Abstract

Antimicrobial peptides (AMPs) play a critical role in controlling innate and acquired immune responses. Local dysregulation of AMP is implicated in the pathogenesis of periodontal diseases as a response to periodontal pathogen challenge. Changes in AMP expression also characterize tobacco smoking, diabetes mellitus, obesity and rheumatoid arthritis, which are established risk factors of periodontal diseases, suggesting AMP may act as putative mechanistic links between these. The aim was to evaluate and summarize critically the current evidence pertaining to interrelationships between AMPs, periodontal diseases and selected periodontal disease risk factors. General and theme specific keywords were used to search the PUBMED database for studies relevant to AMP, periodontal diseases, smoking, diabetes mellitus, obesity and rheumatoid arthritis and critically reviewed. A total of 131 abstracts and 119 full text articles were screened for relevance; 13 studies were selected for inclusion after critical review. Local AMP dysregulation characteristic to periodontal diseases appears to occur within a broader landscape of complex systemic immune perturbations independently induced by smoking, metabolic and rheumatoid disease. The nature of these interactions and mechanistic pathways involved are inadequately understood. AMPs could be possible mechanistic interlinks between periodontal diseases and its risk factors. However, such evidence is very limited and more in vivo and in vitro studies are necessary to clarify the nature of such relationships. A greater understanding of AMPs as shared mediators is essential for unraveling their value as therapeutic or biomarker candidates.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  antimicrobial peptides; cigarette smoking; diabetes mellitus; periodontitis; rheumatoid arthritis; risk factors

Mesh:

Substances:

Year:  2017        PMID: 28990193     DOI: 10.1111/jre.12482

Source DB:  PubMed          Journal:  J Periodontal Res        ISSN: 0022-3484            Impact factor:   4.419


  6 in total

1.  Associations between inflammation-related LL-37 with subgingival microbial dysbiosis in rheumatoid arthritis patients.

Authors:  Chia Wei Cheah; Anis Rageh Al-Maleki; Rathna Devi Vaithilingam; Jamuna Vadivelu; Sargunan Sockalingam; Nor Adinar Baharuddin; Peter Mark Bartold
Journal:  Clin Oral Investig       Date:  2022-03-07       Impact factor: 3.573

2.  Hybrid Hydrogels for Synergistic Periodontal Antibacterial Treatment with Sustained Drug Release and NIR-Responsive Photothermal Effect.

Authors:  Jian Lin; Zhiqi He; Fen Liu; Jie Feng; Chengyi Huang; Xueli Sun; Hui Deng
Journal:  Int J Nanomedicine       Date:  2020-07-29

3.  Serum and salivary ferritin and Hepcidin levels in patients with chronic periodontitis and type 2 diabetes mellitus.

Authors:  Lin-Na Guo; Yan-Zong Yang; Yun-Zhi Feng
Journal:  BMC Oral Health       Date:  2018-04-10       Impact factor: 2.757

4.  Grinspan syndrome with periodontitis: Coincidence or correlation?

Authors:  Lata Goyal; Narinder Dev Gupta; Namita Gupta
Journal:  J Indian Soc Periodontol       Date:  2018 May-Jun

5.  A novel peptide RIFV suppresses human adipocyte differentiation through the inhibition of C/EBP-β expression.

Authors:  Wen Zhang; Dan Shen; Yun Li; Hong Zhong; Xing Wang; Xian-Wei Cui; Chun-Mei Shi; Chen-Bo Ji; Xi-Rong Guo; Ling Chen
Journal:  Nutr Metab (Lond)       Date:  2019-12-23       Impact factor: 4.169

Review 6.  The Best Peptidomimetic Strategies to Undercover Antibacterial Peptides.

Authors:  Joanna Izabela Lachowicz; Kacper Szczepski; Alessandra Scano; Cinzia Casu; Sara Fais; Germano Orrù; Barbara Pisano; Monica Piras; Mariusz Jaremko
Journal:  Int J Mol Sci       Date:  2020-10-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.